Time from amyotrophic lateral sclerosis symptom onset to key disease milestones: analysis of data from a multinational cross-sectional survey

被引:4
作者
Gebrehiwet, Paulos [1 ,5 ]
Brekke, Johan [2 ]
Rudnicki, Stacy A. [3 ]
Mellor, Jennifer [4 ]
Wright, Jack [4 ]
Earl, Lucy [4 ]
Ball, Nathan [4 ]
Iqbal, Halima [4 ]
Thomas, Owen [4 ]
Castellano, Giorgio [4 ]
机构
[1] Cytokinetics Inc, Hlth Econ & Outcomes Res, South San Francisco, CA USA
[2] Cytokinetics Inc, Med Affairs, South San Francisco, CA USA
[3] Cytokinetics Inc, Clin Res, South San Francisco, CA USA
[4] Adelphi Real World, Real World Evidence, Bollington, England
[5] Cytokinetics Inc, Hlth Econ & Outcomes Res, 350 Oyster Point Blvd, South San Francisco, CA 94080 USA
关键词
Amyotrophic lateral sclerosis; clinical milestones; progression; multinational; ALS; BODY-MASS INDEX; STAGING SYSTEM; ALSFRS-R; PROGRESSION; SURVIVAL; DIAGNOSIS; EPIDEMIOLOGY; PROGNOSIS; PATIENT; RISK;
D O I
10.1080/21678421.2023.2297795
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveTo determine the average time from Amyotrophic Lateral Sclerosis (ALS) symptom onset to 11 pre-defined milestones, overall and according to ALS progression rate and geographic location.MethodsData were drawn from the Adelphi Real World ALS Disease-Specific ProgrammeTM, a point-in-time survey of neurologists caring for people living with ALS (pALS) conducted in France, Germany, Italy, Spain, the United Kingdom and the United States from 2020-2021. ALS progression rate was calculated using time since symptom onset and ALS Functional Rating Scale Revised score.ResultsSurvey results were available for N = 1003 pALS (progression rate for N = 867). Mean time from symptom onset was 3.8 months to first consultation, 8.0 months to diagnosis, 16.2 months to employment change (part-time/sick leave/retirement/unemployment), 17.5 months to use of a walking aid, 18.5 months to first occurrence of caregiver support, 22.8 months to use of a wheelchair, 24.6 months to use of a communication aid, 27.3 months to use of a respiratory aid, 28.6 months to use of gastrostomy feeding, 29.7 months to use of eye gaze technology and 30.3 months to entering a care facility. Multivariate analysis indicated significant effects of fast (versus slow) progression rate on time to reach all 11 milestones, as well as US (versus European) location, age, body mass index and bulbar onset (versus other) on time to reach milestones.ConclusionspALS rapidly reached clinical and disease-related milestones within 30 months from symptom onset. Milestones were reached significantly faster by pALS with fast versus slow progression. Geographic differences were observed.
引用
收藏
页码:345 / 357
页数:13
相关论文
共 52 条
[1]   The epidemiology of ALS: a conspiracy of genes, environment and time [J].
Al-Chalabi, Ammar ;
Hardiman, Orla .
NATURE REVIEWS NEUROLOGY, 2013, 9 (11) :617-628
[2]   EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force [J].
Andersen, Peter M. ;
Abrahams, Sharon ;
Borasio, Gian D. ;
de Carvalho, Mamede ;
Chio, Adriano ;
Van Damme, Philip ;
Hardiman, Orla ;
Kollewe, Katja ;
Morrison, Karen E. ;
Petri, Susanne ;
Pradat, Pierre-Francois ;
Silani, Vincenzo ;
Tomik, Barbara ;
Wasner, Maria ;
Weber, Markus .
EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (03) :360-E24
[3]   Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand [J].
Anderson, P. ;
Benford, M. ;
Harris, N. ;
Karavali, M. ;
Piercy, J. .
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) :3063-3072
[4]  
[Anonymous], 2022, Racial and ethnic diversity in the United States: 2010 Census and 2020 Census
[5]  
[Anonymous], 2023, America is getting older
[6]  
[Anonymous], 2022, Adult Obesity Facts
[7]   Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme [J].
Babineaux, S. M. ;
Curtis, B. ;
Holbrook, T. ;
Milligan, G. ;
Piercy, J. .
BMJ OPEN, 2016, 6 (08)
[8]   A standard operating procedure for King's ALS clinical staging [J].
Balendra, Rubika ;
Al Khleifat, Ahmad ;
Fang, Ton ;
Al-Chalabi, Ammar .
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2019, 20 (3-4) :159-164
[9]   Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis [J].
Beghi, Ettore ;
Millul, Andrea ;
Logroscino, Giancarlo ;
Vitelli, Eugenio ;
Micheli, Anna .
AMYOTROPHIC LATERAL SCLEROSIS, 2008, 9 (03) :163-167
[10]  
Brown RH, 2017, NEW ENGL J MED, V377, P1602, DOI [10.1056/NEJMra1603471, 10.1038/nrdp.2017.85, 10.1016/S0140-6736(17)31287-4, 10.1056/NEJMc1710379]